Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials

Background. Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial. The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 2...

Full description

Bibliographic Details
Main Authors: Chen, Yan-xian, Yang, Qiong, Kuang, Jun-jie, Chen, Shi-yu, Wei, Ying, Jiang, Zhi-min, Xie, De-rong
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058184/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058184/

Similar Items